Tag Archives: Jakafi

Incyte the latest to fall victim to JAK scrutiny as FDA pushes back Jakafi review in GVHD

The entire JAK inhibitor family of medicines is feeling the ripple effects from a safety signal flagged for Pfizer’s Xeljanz. Now, the first marketed drug in the class is encountering increased scrutiny from the FDA. The FDA has pushed back a decision for Incyte’s application for Jakafi in steroid-refractory chronic graft-versus-host disease (GVHD) by three months, the… Read More »